35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of cancer driver genes based on nucleotide context

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer genomes contain large numbers of somatic mutations, but few of these mutations drive tumor development. Current approaches identify driver genes based on mutational recurrence, or they approximate the functional consequences of nonsynonymous mutations using bioinformatic scores. While passenger mutations are enriched in characteristic nucleotide contexts, driver mutations occur in functional positions, which are not necessarily surrounded by a particular nucleotide context. We observed that mutations in contexts that deviate from the characteristic contexts around passenger mutations provide a signal in favor of driver genes. We therefore developed a method that combines this feature with the signals traditionally used for driver gene identification. We applied our method to whole-exome sequencing data from 11,873 tumor-normal pairs and identified 460 driver genes that clustered into 21 cancer-related pathways. Our study provides a resource of driver genes across 28 tumor types with additional driver genes identified based on mutations in unusual nucleotide contexts.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

          The cBioPortal for Cancer Genomics (http://cbioportal.org) provides a Web resource for exploring, visualizing, and analyzing multidimensional cancer genomics data. The portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression, and proteomic events. The query interface combined with customized data storage enables researchers to interactively explore genetic alterations across samples, genes, and pathways and, when available in the underlying data, to link these to clinical outcomes. The portal provides graphical summaries of gene-level data from multiple platforms, network visualization and analysis, survival analysis, patient-centric queries, and software programmatic access. The intuitive Web interface of the portal makes complex cancer genomics profiles accessible to researchers and clinicians without requiring bioinformatics expertise, thus facilitating biological discoveries. Here, we provide a practical guide to the analysis and visualization features of the cBioPortal for Cancer Genomics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

            Recent genomic analyses of pathologically defined tumor types identify "within-a-tissue" disease subtypes. However, the extent to which genomic signatures are shared across tissues is still unclear. We performed an integrative analysis using five genome-wide platforms and one proteomic platform on 3,527 specimens from 12 cancer types, revealing a unified classification into 11 major subtypes. Five subtypes were nearly identical to their tissue-of-origin counterparts, but several distinct cancer types were found to converge into common subtypes. Lung squamous, head and neck, and a subset of bladder cancers coalesced into one subtype typified by TP53 alterations, TP63 amplifications, and high expression of immune and proliferation pathway genes. Of note, bladder cancers split into three pan-cancer subtypes. The multiplatform classification, while correlated with tissue-of-origin, provides independent information for predicting clinical outcomes. All data sets are available for data-mining from a unified resource to support further biological discoveries and insights into novel therapeutic strategies. Copyright © 2014 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology

              BindingDB, www.bindingdb.org, is a publicly accessible database of experimental protein-small molecule interaction data. Its collection of over a million data entries derives primarily from scientific articles and, increasingly, US patents. BindingDB provides many ways to browse and search for data of interest, including an advanced search tool, which can cross searches of multiple query types, including text, chemical structure, protein sequence and numerical affinities. The PDB and PubMed provide links to data in BindingDB, and vice versa; and BindingDB provides links to pathway information, the ZINC catalog of available compounds, and other resources. The BindingDB website offers specialized tools that take advantage of its large data collection, including ones to generate hypotheses for the protein targets bound by a bioactive compound, and for the compounds bound by a new protein of known sequence; and virtual compound screening by maximal chemical similarity, binary kernel discrimination, and support vector machine methods. Specialized data sets are also available, such as binding data for hundreds of congeneric series of ligands, drawn from BindingDB and organized for use in validating drug design methods. BindingDB offers several forms of programmatic access, and comes with extensive background material and documentation. Here, we provide the first update of BindingDB since 2007, focusing on new and unique features and highlighting directions of importance to the field as a whole.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                18 December 2019
                03 February 2020
                February 2020
                03 August 2020
                : 52
                : 2
                : 208-218
                Affiliations
                [1 ]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
                [2 ]Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, 02142, USA.
                [3 ]Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
                [4 ]Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
                [5 ]Centre for Genomic Regulation, 08003 Barcelona, Spain.
                [6 ]Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
                [7 ]These authors contributed equally: Felix Dietlein, Donate Weghorn.
                [8 ]These authors jointly supervised this work: Eliezer M. Van Allen, Shamil R. Sunyaev.
                Author notes

                Author contributions F.D. and D.W. contributed equally to this work. E.M.V. and S.R.S. jointly supervised this work. F.D., D.W, A.R., E.S.L., E.M.V. and S.R.S. wrote the manuscript and prepared the figures, which all authors reviewed. F.D., D.W., B.R., D.L., E.M.V. and S.R.S. designed and performed the bioinformatics analyses for driver gene identification. F.D., D.W., B.R., D.L., E.M.V. and S.R.S. designed and performed the bioinformatics analyses for method comparison and stratification of the driver gene catalog. F.D., D.W., A.T.-W., A.R., B.R., D.L., E.S.L., E.M.V. and S.R.S. performed a review of the findings and biological follow-up analyses. F.D., D.W., A.T.-W., B.R., D.L., E.S.L., E.M.V. and S.R.S. contributed to the development of the method and its implementation.

                Article
                NIHMS1546846
                10.1038/s41588-019-0572-y
                7031046
                32015527
                52bb80dd-7147-4b7a-b5b8-256fd3784f55

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article